此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

初次全髋关节置换术中的髋关节置换系统 (HRS-P) ((HRS-P))

2026年9月16日 更新者:Hip Innovation Technology

髋关节创新技术(HIT)髋关节置换系统在初次全髋关节置换术中的多中心前瞻性研究

To evaluate effectiveness and safety of HHRS in subjects undergoing total hip arthroplasty (THA). Effectiveness will be evaluated using patient-reported, clinical, radiologic, and radiostereometric outcomes. Safety will be evaluated through the collection of device-related and unanticipated device-related adverse events.

研究概览

地位

招聘中

详细说明

The HIT Hip Replacement System (HHRS) is a Metal-on-Polyethylene (MoP) conventional hip prosthesis. The HHRS consists of a femoral stem, an acetabular cup and a Cobalt Chromium Molybdenum (CoCrMo) ball that articulates within a polyethylene liner. The ball sits on the acetabular cup, and the polyethylene liner is attached to the femoral cup, which attaches to the femoral stem, instead of the acetabular cup. The acetabular component of the HHRS consists of a hemispherical acetabular shell with a clustered screw-hole design. The outside of the shells are coated with titanium plasma to facilitate bone in-growth and provide secure intermediate fixation with the prepared bone surface at the site of implantation. The acetabular cup has a 3-hole design that accommodates three titanium alloy bone screws. Inside the acetabular cup is a male taper for assembly with the acetabular ball. The femoral component consists of a femoral stem manufactured from titanium and a mating cobalt chrome femoral cup lined with a highly cross-linked ultra-high-molecular-weight polyethylene (UHMWPE). As with the acetabular cup, the femoral stem is porous coated using a plasma spray of pure titanium, which is intended to facilitate bone in-growth and provide secure intermediate fixation with the prepared bone surface at the site of implantation. The femoral stem incorporates a female taper for assembly with the male taper of the femoral cup.

The device has undergone extensive pre-clinical testing. There is no clinical experience with the HRS.

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Thomas Turgeon, MD
  • 电话号码:204-926-1218
  • 邮箱:tturgeon@cjrg.ca

学习地点

    • Manitoba
      • Winnipeg、Manitoba、加拿大、R2K 2M9
        • 招聘中
        • Orthopaedic Innovation Centre
        • 接触:
        • 接触:
        • 首席研究员:
          • Thomas Turgeon, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 至 79年 (年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patient has a non-inflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses such as osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fracture of the pelvis, and diastrophic variant requiring unilateral primary total hip replacement.
  • Age between 65 and 79 years (inclusive) at the time of enrollment.
  • Patient is a suitable candidate for primary total hip replacement at the discretion of the Investigator.
  • Pre-surgery (within 28 days before surgery) WOMAC Global Score of 40 or larger on a scale from 0 (best) to 96 (worst)
  • Signed and dated informed consent document.
  • Patient is willing and able to participate in required follow-up visits at the Investigational site and to complete study procedures and questionnaires.

Exclusion Criteria:

  • Patient has had total hip replacement, hemi-arthroplasty, or fusion in either hip in the last 12 months;
  • Patient has planned total hip arthroplasty on a contra-lateral joint in the next 12 months;
  • Patient has a known allergy to any component of the study device;
  • Patient has a history of active sepsis in the joint;
  • Patient has an insufficient acetabular or femoral bone stock in which good anchorage of the implants are unlikely or impossible;
  • Patient has total or partial absence of the muscular or ligamentous apparatus;
  • Patient has known moderate to severe renal insufficiency;
  • Patient has vascular insufficiency, muscular atrophy, or neuromuscular disease in either leg (based on the Investigator's discretion);
  • Patient has a deformity of the affected limb or significant anatomic variance of the affected hip;
  • Patient has an active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix definitively treated more than 1 year prior to enrollment may enter the study;
  • Patient has any condition which may, in the opinion of the Investigator, interfere with the total hip replacement survival or patient outcomes (e.g. Paget's disease, Charcot's disease);
  • Patient has rheumatoid arthritis or other autoimmune condition that affect joints (e.g. Lupus Arthritis);
  • Patient has any condition that would interfere with patient self-assessment or pain, the function or quality of life required for patient reported outcomes during the study (based on the Investigator's discretion);
  • Body Mass Index (BMI) of 40 or more;
  • Patient has an active infection (e.g. hepatitis, AIDS, ARC) - systemic or at the site of intended surgery;
  • Patient is currently participating in any investigational study not related to this study's pre-operative or post-operative care;
  • Patient has any other severe acute or chronic medical condition that may interfere with the interpretation of the study results, in the judgment of the Investigator, which would make the patient inappropriate for entry into this study;
  • Patient has a history of metabolic bone disease (e.g. Paget's disease or osteomalacia);
  • Patient is currently pregnant or is planning to become pregnant.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:HIT Hip Replacement System (HRS)

Single group assignment with historical controls.

HIT Hip Replacement System

研究衡量的是什么?

主要结果指标

结果测量
大体时间
西安大略大学和麦克马斯特大学骨关节炎指数 (WOMAC) v3.0 Likert 量表功能限制评分在基线(术前)和术后 730 天随访时间点之间的变化。
大体时间:术前至 730 天(24 个月)
术前至 730 天(24 个月)
Harris 髋关节评分在基线(术前)和术后 730 天随访时间点之间的变化。
大体时间:术前至 730 天(24 个月)
术前至 730 天(24 个月)

次要结果测量

结果测量
大体时间
术后 730 天和基线(术前)之间牛津髋关节评分的变化
大体时间:术后 730 天和基线(术前)之间
术后 730 天和基线(术前)之间
术后 730 天和基线(术前)之间简式 36 v2 物理成分评分 (PCS) 的变化
大体时间:术后 730 天和基线(术前)之间
术后 730 天和基线(术前)之间

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Thomas Turgeon, MD、Orthopaedic Innovation Centre
  • 研究主任:Branko Kopjar, MD, PhD、Nor Consult, LLC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2017年8月25日

初级完成 (估计的)

2029年9月16日

研究完成 (估计的)

2032年9月16日

研究注册日期

首次提交

2016年7月14日

首先提交符合 QC 标准的

2016年7月15日

首次发布 (估计的)

2016年7月18日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • HIT-001

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅